The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.
 
Maria Pagano
No Relationships to Disclose
 
Giovanni Luca Ceresoli
Honoraria - AstraZeneca; Novartis; Novocure
Speakers' Bureau - Novartis; Novocure
Travel, Accommodations, Expenses - Ipsen; Roche; Sanofi
 
Paolo Andrea Zucali
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi
 
Giulia Pasello
Consulting or Advisory Role - AstraZeneca; BMSi; Boehringer Ingelheim; Lilly; MSD
Research Funding - Roche
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Federica Grosso
No Relationships to Disclose
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim
 
Hector J. Soto Parra
No Relationships to Disclose
 
Francesca Zanelli
No Relationships to Disclose
 
Federico Cappuzzo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD Oncology; pfizer; Roche/Genentech; Takeda
 
Francesco Grossi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pierre Fabre; Roche
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche/Genentech
 
Paolo Pedrazzoli
No Relationships to Disclose
 
Roberta Gnoni
No Relationships to Disclose
 
Candida Bonelli
No Relationships to Disclose
 
Annalisa Berselli
No Relationships to Disclose
 
Luca Boni
No Relationships to Disclose
 
Nicola Normanno
No Relationships to Disclose
 
Carmine Pinto
No Relationships to Disclose